These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18064056

  • 1. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.
    Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, Fernandez M.
    Eye (Lond); 2009 Feb; 23(2):334-8. PubMed ID: 18064056
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
    Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S.
    Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM, Lai TY, Liu DT, Lam DS.
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP.
    Retina; 2010 Dec; 30(10):1609-15. PubMed ID: 20856171
    [Abstract] [Full Text] [Related]

  • 7. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
    Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M.
    Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome.
    Ruiz-Moreno JM, Montero JA.
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):937-41. PubMed ID: 20221624
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
    Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solís-Vivanco A, Reyna-Castelán E, Abraham-Marín M, Martínez-Castellanos MA, Aiello LP.
    Retina; 2007 Jul; 27(6):707-12. PubMed ID: 17621179
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Jul; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 19. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.
    Ruiz-Moreno JM, Montero JA, Amat-Peral P.
    Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):595-9. PubMed ID: 21234588
    [Abstract] [Full Text] [Related]

  • 20. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
    Yodoi Y, Tsujikawa A, Nakanishi H, Otani A, Tamura H, Ojima Y, Hayashi H, Yoshimura N.
    Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.